C-POST Trial Results: Adjuvant Immunotherapy (Cemiplimab) in Cutaneous SCC with Dr. Danny Rischin, MD

In a recent episode of MedInsights Unleashed, Dr. Danny Rischin, MD, medical oncologist/clinician researcher at the Peter MacCallum Cancer Centre and Professor, Sir Peter MacCallum Department of Oncology, University of Melbourne, discusses the groundbreaking C-POST study focused on cutaneous squamous cell cancer. By utilizing the immunotherapy drug, cemiplimab, the study achieves a 68% reduction in the risk of recurrence, marking a significant step forward in adjuvant cancer therapy. Dr. Rischin explains the study’s meticulous approach to identifying high-risk patients and its impressive 87% disease-free survival rate at two years. He also discusses the role of multidisciplinary care in effectively managing complex cancer cases, emphasizing the need for continued research in uncovering reliable biomarkers.

 

Leave a Reply